Price Alert

Inhibrx Biosciences Inc. (INBX)

NASDAQ: INBX · Real-Time Price · USD

32.68

0.84 (2.62%)

At close: Sep 26, 2025, 3:59 PM

32.68

0.00%

After-hours: Sep 26, 2025, 07:22 PM EDT

Inhibrx Biosciences Statistics

Share Statistics

Inhibrx Biosciences has 14.49M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	14.49M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	69.99%
Shares Floating	9.86M
Failed to Deliver (FTD) Shares	95
FTD / Avg. Volume	0.07%

Short Selling Information

The latest short interest is 721.5K, so 4.98% of the outstanding shares have been sold short.

Short Interest	721.5K
Short % of Shares Out	4.98%
Short % of Float	6.87%
Short Ratio (days to cover)	7.53

Valuation Ratios

The PE ratio is 0.13 and the forward PE ratio is -3.42. Inhibrx Biosciences's PEG ratio is 0.

PE Ratio	0.13
Forward PE	-3.42
PS Ratio	1114.64
Forward PS	109.6
PB Ratio	1.67
P/FCF Ratio	-1.13
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Inhibrx Biosciences has an Enterprise Value (EV) of 78.38M.

EV / Sales	391.9
EV / EBITDA	0.05
EV / EBIT	-0.4
EV / FCF	-0.4

Financial Position

The company has a current ratio of 3.94, with a Debt / Equity ratio of 0.06.

Current Ratio	3.94
Quick Ratio	3.94
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.04
Interest Coverage	-24.57

Financial Efficiency

Return on Equity is 1263.3% and Return on Invested Capital is -234.02%.

Return on Equity	1263.3%
Return on Assets	933.56%
Return on Invested Capital	-234.02%
Revenue Per Employee	$1.28K
Profits Per Employee	$10.82M
Employee Count	156
Asset Turnover	0
Inventory Turnover	n/a

Taxes

Income Tax	2K
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 110.57% in the last 52 weeks. The beta is 0.31, so Inhibrx Biosciences's price volatility has been higher than the market average.

Beta	0.31
52-Week Price Change	110.57%
50-Day Moving Average	25.35
200-Day Moving Average	16.81
Relative Strength Index (RSI)	74.75
Average Volume (20 Days)	142,592

Income Statement

In the last 12 months, Inhibrx Biosciences had revenue of 200K and earned 1.69B in profits. Earnings per share was 116.58.

Revenue	200K
Gross Profit	-2.08M
Operating Income	-331.45M
Net Income	1.69B
EBITDA	1.7B
EBIT	1.7B
Earnings Per Share (EPS)	116.58

Full Income Statement

Balance Sheet

The company has 152.6M in cash and 8.05M in debt, giving a net cash position of 144.55M.

Cash & Cash Equivalents	152.6M
Total Debt	8.05M
Net Cash	144.55M
Retained Earnings	-106.13M
Total Assets	212.12M
Working Capital	155.03M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -194.41M and capital expenditures -2.6M, giving a free cash flow of -197.01M.

Operating Cash Flow	-194.41M
Capital Expenditures	-2.6M
Free Cash Flow	-197.01M
FCF Per Share	-13.61

Full Cash Flow Statement

Margins

Gross margin is -1042.5%, with operating and profit margins of -165724% and 843786%.

Gross Margin	-1042.5%
Operating Margin	-165724%
Pretax Margin	843787%
Profit Margin	843786%
EBITDA Margin	851675%
EBIT Margin	-165724%
FCF Margin	-98503%

Dividends & Yields

INBX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	757%
FCF Yield	-88.37%

Dividend Details

Analyst Forecast

Currently there are no analyst rating for INBX.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	155.58
Graham Upside	376.07%

Scores

Altman Z-Score	-1.06
Piotroski F-Score	3